Clinical Guidelines: Dosing and Switching Strategies for Long-Acting Risperidone

View This PDF

NB: This article is only available as a PDF.

Because this piece has no abstract, we have provided for your benefit the first 3 sentences of the full text.

The availability of a long-acting injectable atypical antipsychotic may increase compliance with medication regimens in patients with schizophrenia. Currently, long-acting risperidone is the only such agent. It is now available or approved in 33 countries, including Austria, Germany, Mexico, the Netherlands, New Zealand, and the United Kingdom.​​

J Clin Psychiatry 2003;64(suppl 16):41-46